A Study of Interactions between Pharmaceutical Representatives and Ophthalmology Trainees

American Journal of Ophthalmology

Volumn 148, Issue 4, 2009, Pages

  Wang, Yue ^a,b   Adelman, Ron A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; BEHAVIOR; COMPARATIVE STUDY; EVALUATION; HEALTH CARE POLICY; HEALTH PERSONNEL ATTITUDE; HEALTH PROMOTION; MEDICAL INFORMATION; MEDICAL STUDENT; OPHTHALMOLOGY; PEER GROUP; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; QUESTIONNAIRE; RESIDENCY EDUCATION; SAMPLE; SCORING SYSTEM; UNITED STATES;

EID: 70349281440     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.05.011     Document Type: Article

References (18)

1. Zuger A. Fever pitch: getting doctors to prescribe is big business (January 11, 1999), New York Times 1 Section A
2. Stolberg S.G., and Gerth J. High-tech stealth being used to sway doctor prescriptions (November 16, 2000), New York Times 1 Section A
3. Zuger A. When your doctor goes to the beach, you may get burned (February 24, 2004), New York Times 5 Section F
4. Angell M. The Truth about the Drug Companies: How They Deceive Us and What to Do about It (2004), Random House, New York, New York
5. Avorn J., Chen M., and Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 73 (1982) 4-8
6. Peay M.Y., and Peay E.R. The role of commercial sources in the adoption of a new drug. Soc Sci Med 26 (1988) 1183-1189
7. Chren M.M., and Landefeld C.S. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 271 (1994) 684-689
8. Orlowski J.P., and Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 102 (1992) 270-273
9. Steinman M.A., Shlipak M.G., and McPhee S.J. Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 110 (2001) 551-557
10. Keim S.M., Sanders A.B., Witzke D.B., Dyne P., and Fulginiti J.W. Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry. Ann Emerg Med 22 (1993) 1576-181
11. Schwartz T.L., Kuhles II D.J., Wade M., and Masand P.S. Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits. Ann Clin Psychiatry 13 (2001) 159-162
12. Boltri J.M., Gordon E.R., and Vogel R.L. Effect of antihypertensive samples on physician prescribing patterns. Fam Med 34 (2002) 729-731
13. SoRelle R. Tougher rules keep pharmaceutical reps out of EDs. Emerg Med News 26 (2004) 1 36
14. Lichter P.R. Debunking myths in physician-industry conflicts of interest. Am J Ophthalmol 146 (2008) 159-171
15. Lichter P.R. Continuing medical education, physicians, and Pavlov: can we change what happens when industry rings the bell?. Arch Ophthalmol 126 (2008) 1593-1597
16. Reeder M., Dougherty J., and White L.J. Pharmaceutical representatives and emergency medicine residents: a national survey. Ann Emerg Med 22 (1993) 1593-1596
17. McCormick B.B., Tomlinson G., Brill-Edwards P., and Detsky A.S. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA 286 (2001) 1994-1999
18. Tuffs A. Only 6% of drug advertising material is supported by evidence. BMJ 328 (2004) 485